Radyus Research
Radyus Research is an Atlanta-based R&D operating partner that delivers a fully integrated PMO for VC- and PE-backed biotech companies, consolidating strategy, regulatory, CMC, nonclinical, clinical, and program management into one accountable execution layer from preclinical through clinical proof of concept.
- Company typePrivate
- Founded2019
- HeadquartersAtlanta, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Radyus Research does
Radyus Research & Development, Inc. is an Atlanta-based, privately held professional services firm founded in 2019 that operates as an embedded R&D operating partner for VC- and PE-backed biotech companies. Rather than selling software or discrete CRO services, the company delivers a fully integrated Program Management Organization (PMO) that consolidates strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution layer spanning preclinical through clinical proof of concept. Its service bundle comprises eight functional modules — Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy — sold as one cohesive engagement rather than à la carte components.
The company's operating model relies on a curated global network of CROs, CDMOs, and specialist partners (including Southern Research, Dt&CRO, and Eurofins CDMO Alphora) to provide execution capacity without internal infrastructure build. Therapeutic area coverage spans oncology, immunology, CNS, and metabolic diseases. Go-to-market is enterprise field sales targeting executive leadership and boards of VC/PE-backed portfolio companies, with custom-quoted pricing structured around program scope, duration, and complexity (no public pricing). The customer base is segmented into three primary personas — PE-Backed Platforms, Venture Studios, and VC-Backed Biotech — each requiring portfolio-level discipline, capital efficiency, and credible execution under investor and regulatory scrutiny. Revenue mechanics are managed-services style, likely retainer or milestone-based, but no revenue figures are disclosed.
Radyus is led by Co-founder and CEO Marta New, PhD, MBA, President and COO Kelly R. Pitts, PhD, and Co-founder and Director Paul Tebbey, PhD, MBA, supported by functional heads across development, clinical operations, scientific operations, CMC/manufacturing, toxicology, and project management. The company is privately held with only $200,000 in disclosed funding (raised in February 2020), implying services revenue has funded operations. Recent strategic activity includes three named CRO/CDMO partnerships (2024-2025), a South Korea-U.S. cross-border channel via Dt&CRO, and a May 2026 leadership and brand expansion.
Radyus Research firmographics
Firmographics- Name
- Radyus Research
- Legal name
- Radyus Research & Development, Inc.
- Website
- https://radyusresearch.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Radyus Research is an Atlanta-based R&D operating partner that delivers a fully integrated PMO for VC- and PE-backed biotech companies, consolidating strategy, regulatory, CMC, nonclinical, clinical, and program management into one accountable execution layer from preclinical through clinical proof of concept.
- Ownership category
- akta.pro rank
Radyus Research industry classification
Industry- Product category
- Biotech R&D Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC)
Keywords
Where Radyus Research is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Radyus Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- R&D Program Management Services: Full-service R&D operating partnership providing end-to-end drug development services from preclinical through clinical proof of concept. Revenue derived from professional services engagements with VC/PE-backed biotech companies, likely structured as retainer or milestone-based contracts.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Radyus Research product offering
Product offeringCore offering
Radyus Research provides a fully integrated Program Management Organization (PMO) service that plans, executes, and owns drug development end-to-end, from preclinical through clinical proof of concept. The offering bundles development strategy and indication selection, regulatory pathway and agency engagement, CMC and manufacturing strategy, nonclinical and translational planning, clinical development and trial operations, program and portfolio management, diligence and asset readiness, and commercial and exit strategy into a single accountable operating layer for VC/PE-backed biotech companies.
Product overview
Radyus Research offers a single, unified service offering: a fully integrated R&D Program Management Organization (PMO) that serves as an embedded operating partner for VC/PE-backed biotech companies. The core PMO service integrates eight distinct functional modules—Development Strategy & Indication Selection, Regulatory Pathway & Agency Engagement, CMC & Manufacturing Strategy, Nonclinical & Translational Planning, Clinical Development & Trial Operations, Program & Portfolio Management, Diligence & Asset Readiness, and Commercial & Exit Strategy—into one cohesive execution engine. Rather than selling separate software products or modules, Radyus delivers its expertise as a bundled service, replacing fragmented vendor stacks with a single accountable operating layer that aligns regulatory and manufacturing strategy with preclinical and clinical execution from preclinical through clinical proof of concept.
Differentiator
Problem solved
Functional benefit
Products and services
- R&D Program Management Organization (PMO) Services Fully integrated Program Management Organization service that plans, executes, and owns drug development end-to-end for VC/PE-backed biotech companies. Acts as an embedded R&D PMO combining strategy, regulatory, CMC, nonclinical, clinical, and program management into a single accountable execution engine.
Companies that use Radyus Research
Customer profileSegments3 records
Ideal customer profiles3 records
Radyus Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Radyus Research partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Eurofins CDMO AlphoracoreStrategic partnership to accelerate and optimize drug development. Eurofins CDMO Alphora provides integrated manufacturing with high-quality CMC development and GMP production capabilities across early and mid-stage programs.
- Dt&CROcoreJoint partnership to pave the way for South Korean biotech companies into the U.S. market. Dt&CRO is a Korean-based CRO specializing in non-clinical and clinical studies across therapeutic areas, known for operational scale and execution quality.
- Southern ResearchcoreStrategic partnership to propel life sciences commercialization. Southern Research provides preclinical CRO capabilities and specialized scientific platforms supporting nonclinical development.
- CDMO NetworkminorCurated network of Contract Development and Manufacturing Organizations providing integrated CMC planning and phase-appropriate manufacturing readiness.
- CRO NetworkminorNetwork of Clinical Research Organizations supporting nonclinical and clinical studies across therapeutic areas.
Scale indicators1 record
Recent moves5 records
Expansion highlights5 records
Radyus Research competitors and assessment
Company assessmentBroad incumbents
- IQVIA: IQVIA is the world's largest CRO with biotech-dedicated units and integrated clinical, regulatory and real-world services — the most scaled incumbent offering an end-to-end alternative to Radyus's PMO model.
- Medpace: Medpace is a mid-size full-service CRO with a strong biotech and venture-backed sponsor book and a reputation for full-service program execution — the closest publicly traded analog to Radyus's integrated PMO model.
- ICON plc: ICON is a top-tier global CRO with biotech-focused divisions and integrated clinical and laboratory services, competing for the same emerging-biotech program work Radyus targets.
- Charles River Laboratories: Charles River is a major CRO/CDMO covering preclinical, CMC and clinical services across all sponsor sizes; its integrated early-stage development offering competes with Radyus's PMO coordination of preclinical and CMC work.
Direct peers
- Allucent: Allucent is a mid-size CRO purpose-built for small and mid-cap biotechs with integrated clinical and regulatory services, closely paralleling Radyus's positioning as a specialized operating partner for emerging biotech rather than a full-scale broad CRO.
- Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size CRO focused on complex therapeutic areas and small/mid biotech sponsors, offering integrated clinical operations and program management that overlaps directly with Radyus's clinical and nonclinical execution scope.
- Rho: Rho is a privately held CRO specifically focused on emerging biotech and complex clinical programs, with integrated data, regulatory and clinical operations services — a comparable mid-size, science-led operating partner.
- ProPharma Group: ProPharma Group combines life sciences consulting with compliance, regulatory and clinical services for pharma and biotech, comparable to Radyus's bundled PMO-and-strategy delivery model for under-resourced biotech teams.
- Camargo Pharmaceutical Services: Camargo provides integrated drug development, regulatory strategy and 505(b)(2) services to small and mid-sized biopharma, mirroring Radyus's emphasis on regulatory pathway design and end-to-end program ownership for emerging biotech clients.
Others
- Eurofins CDMO: Eurofins CDMO is one of Radyus's named strategic partners for CMC and GMP manufacturing, making it a relevant ecosystem participant rather than a direct competitor — comparable because it is part of the curated execution network the PMO model relies on.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Radyus Research social profiles
Digital presenceRadyus Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Radyus Research leadership team
Management profileNumber of profiles
Profiles16 records
Radyus Research funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Radyus Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Radyus Research
What does Radyus Research do?
Radyus Research provides a fully integrated Program Management Organization (PMO) service that plans, executes, and owns drug development end-to-end, from preclinical through clinical proof of concept. The offering bundles development strategy and indication selection, regulatory pathway and agency engagement, CMC and manufacturing strategy, nonclinical and translational planning, clinical development and trial operations, program and portfolio management, diligence and asset readiness, and commercial and exit strategy into a single accountable operating layer for VC/PE-backed biotech companies.
Is Radyus Research a public or private company?
Radyus Research is a private company. It is classified as unknown and is currently operating.
When was Radyus Research founded?
Radyus Research was founded in 2019. It employs 11 to 50 people.
Where is Radyus Research based?
Radyus Research is headquartered in Atlanta, United States, in the North America region.
How does Radyus Research make money?
One revenue line is on record: R&D Program Management Services.
Who are Radyus Research's main competitors?
Broad incumbents on record are IQVIA, Medpace, ICON plc and Charles River Laboratories. Direct peers are Allucent, Worldwide Clinical Trials, Rho, ProPharma Group and Camargo Pharmaceutical Services. Eurofins CDMO is listed as an others.
Does Radyus Research have an API?
No public API is recorded for Radyus Research.
What industry is Radyus Research in?
Radyus Research's product category is Biotech R&D Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 8731.